Holen Sie sich die Stockscreener-App
3.16
9.20%
-0.32
Handel nachbörslich:
3.18
0.02
+0.63%
Schlusskurs vom Vortag:
$3.48
Offen:
$3.52
24-Stunden-Volumen:
112.40K
Relative Volume:
1.29
Marktkapitalisierung:
$49.86M
Einnahmen:
$19.91M
Nettoeinkommen (Verlust:
$-127.11M
KGV:
-4.0544
EPS:
-0.7794
Netto-Cashflow:
$-132.44M
1W Leistung:
-17.28%
1M Leistung:
-10.99%
6M Leistung:
-39.81%
1J Leistung:
-21.98%
1-Tages-Spanne:
$3.14
$3.54
1-Wochen-Bereich:
$3.14
$4.0413
52-Wochen-Spanne:
$2.9178
$8.95
Affimed N V Stock (AFMD) Company Profile
Vergleichen Sie AFMD mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
| AFMD | 3.16 | 49.86M | 19.91M | -127.11M | -132.44M | -0.7794 |
| VRTX | 467.01 | 119.87B | 10.63B | -479.80M | -1.35B | 13.33 |
| REGN | 762.00 | 83.27B | 13.85B | 4.65B | 3.32B | 35.06 |
| ARGX | 567.90 | 33.96B | 1.86B | -40.29M | -1.28B | -4.16 |
| ALNY | 232.27 | 30.18B | 2.09B | -332.26M | 16.06M | -4.14 |
| BNTX | 101.87 | 24.42B | 3.30B | -501.07M | 1.03B | 11.54 |
Affimed N V Stock (AFMD) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2022-12-12 | Eingeleitet | H.C. Wainwright | Buy |
| 2022-10-10 | Herabstufung | Stifel | Buy → Hold |
| 2022-08-18 | Fortgesetzt | Wells Fargo | Overweight |
| 2022-03-31 | Eingeleitet | Piper Sandler | Overweight |
| 2022-02-23 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2021-10-21 | Eingeleitet | Truist | Buy |
| 2021-09-30 | Eingeleitet | Stifel | Buy |
| 2021-03-31 | Eingeleitet | Credit Suisse | Outperform |
| 2019-03-28 | Eingeleitet | SVB Leerink | Outperform |
| 2018-08-28 | Hochstufung | Jefferies | Hold → Buy |
| 2017-07-14 | Eingeleitet | SunTrust | Buy |
| 2016-08-12 | Herabstufung | Leerink Partners | Outperform → Mkt Perform |
| 2016-05-19 | Herabstufung | Leerink Partners | Outperform → Mkt Perform |
| 2015-12-10 | Eingeleitet | Laidlaw | Buy |
| 2015-12-04 | Eingeleitet | Wells Fargo | Outperform |
| 2015-09-09 | Eingeleitet | Jefferies | Hold |
| 2015-08-06 | Bestätigt | Oppenheimer | Outperform |
| 2015-06-22 | Bestätigt | Jefferies | Buy |
Alle ansehen
Affimed N V Aktie (AFMD) Neueste Nachrichten
Affimed N.V. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com
Stifel Nicolaus Cuts Affimed (NASDAQ:AFMD) Price Target to $4.00 - MarketBeat
Affimed N.V. (NASDAQ:AFMD) Q3 2024 Earnings Call Transcript - Insider Monkey
Affimed's (AFMD) Buy Rating Reiterated at HC Wainwright - MarketBeat
Earnings call: Affimed reports promising results and strategic focus - Investing.com India
Affimed NV (AFMD) Q3 2024 Earnings Call Highlights: Navigating F - GuruFocus.com
Affimed NV (AFMD) Q3 2024 Earnings Call Highlights: Navigating Financial Challenges with ... - Yahoo Finance
Affimed Reports Q3 2024 Financial Results and Updates - TipRanks
Affimed N.V.: Q3 Earnings Snapshot - Milford Mirror
Affimed NV earnings missed by €0.09, revenue fell short of estimates - Investing.com Canada
Affimed Faces Growing Losses Amid Financial Struggles - TipRanks
Affimed Reports Third Quarter 2024 Financial Results & Business Update - The Manila Times
Affimed N.V.: Q3 Earnings Snapshot | National Business News | voiceofalexandria.com - Voice Of Alexandria
Affimed Q3 Revenue Drops 90%, but Net Loss Narrows as R&D Costs Decline | AFMD Stock News - StockTitan
Affimed (AFMD) Scheduled to Post Quarterly Earnings on Thursday - Defense World
Affimed to Report Third Quarter 2024 Financial Results and Corporate Update on November 14, 2024 - Marketscreener.com
Affimed (AFMD) Scheduled to Post Earnings on Thursday - MarketBeat
Affimed to Report Third Quarter 2024 Financial Results & Corporate Update on November 14, 2024 - GlobeNewswire
Affimed (AFMD) Sets Q3 2024 Earnings Call for Nov 14: Immuno-Oncology Updates Ahead | AFMD Stock News - StockTitan
Affimed (NASDAQ:AFMD) Share Price Passes Above 50-Day Moving AverageWhat's Next? - MarketBeat
Affimed Announces Acceptance of Three Abstracts at the 2024 - GlobeNewswire
Affimed to Present Promising AML Treatment Data at ASH 2024 Annual Meeting | AFMD Stock News - StockTitan
Affimed (NASDAQ:AFMD) Receives Consensus Rating of "Buy" from Brokerages - MarketBeat
Affimed (NASDAQ:AFMD) Given Average Rating of “Buy” by Analysts - Defense World
Affimed (NASDAQ:AFMD) Short Interest Update - MarketBeat
683 Capital Management, LLC Expands Stake in Affimed NV - Yahoo Finance
Affimed Appoints New Director Amid Strategic Moves - TipRanks
Affimed N : Annual General Meeting Results Form 6 K - Marketscreener.com
Affimed N : Presentation - Marketscreener.com
Analysts Set Affimed (NASDAQ:AFMD) Target Price at $20.00 - MarketBeat
Affimed Appoints New CEO, Shares Fall on Leadership Change - MSN
Affimed appoints Shawn Leland as chief executive officer - MSN
Affimed (NASDAQ:AFMD) Sees Significant Decrease in Short Interest - MarketBeat
AFMDAffimed N.V. Latest Stock News & Market Updates - StockTitan
Affimed N.V. Announces Upcoming EGM - TipRanks
Affimed to Present at the Cantor Global Healthcare Conference 2024 - GlobeNewswire
Affimed (NASDAQ:AFMD) Receives “Overweight” Rating from Cantor Fitzgerald - Defense World
Cantor Fitzgerald Reiterates "Overweight" Rating for Affimed (NASDAQ:AFMD) - MarketBeat
Affimed (NASDAQ:AFMD) Receives Consensus Rating of "Buy" from Analysts - MarketBeat
Affimed N.V. (NASDAQ:AFMD) Q2 2024 Earnings Call Transcript - Insider Monkey
HC Wainwright Reaffirms Buy Rating for Affimed (NASDAQ:AFMD) - MarketBeat
Earnings call: Affimed reports promising clinical results and stable finances By Investing.com - Investing.com Australia
Earnings call: Affimed reports promising clinical results and stable finances - Investing.com
Affimed NV (AFMD) Q2 2024 Earnings Call Transcript Highlights: F - GuruFocus.com
Affimed N.V.: Q2 Earnings Snapshot - New Haven Register
Affimed to Present Preclinical Data Demonstrating Cytotoxic Activity of its Novel Innate Cell Engager AFM28 at the Annual Meeting of the European Hematology Association (EHA) - Yahoo Finance UK
Stifel holds Affimed at $5 target with new CEO at helm By Investing.com - Investing.com Canada
Stifel holds Affimed at $5 target with new CEO at helm - Investing.com
Finanzdaten der Affimed N V-Aktie (AFMD)
Umsatz
Nettogewinn
Free Cashflow
ENV
3.66%
1.11%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):